Bayer AG Stock Faces Pressure as Activist Investor Inclusive Capital Exits Stake Amid Ongoing US Litigation Challenges

The Bayer AG stock (ISIN: DE000BAY0017) dropped over 2% on Xetra to around 37.65 EUR as activist investor Inclusive Capital sold its remaining 8.5 million shares at a discount, signaling waning confidence. This comes against the backdrop of persistent US Roundup litigation risks, with the Supreme Court set to hear a landmark case that could reshape Bayer's financial future. US investors should watch closely due to Bayer's heavy exposure to American legal and agricultural markets.

Bayer AG stock tumbled more than 2% on Tuesday, pressured by the exit of activist investor Inclusive Capital Partners, which sold its remaining stake in the German pharmaceutical and crop science giant. Shares on Xetra fell to a real-time estimate of 37.65 EUR, down 2.11% amid broader market concerns over the company's ongoing US litigation woes related to Roundup weedkiller claims. This development underscores persistent uncertainties hanging over Bayer, particularly its vulnerability to American tort litigation that has already drained billions from its balance sheet.

As of: 24.03.2026

Dr. Elena Voss, Pharma Sector Analyst: Bayer's dual exposure to innovative therapeutics and legacy agrochemical liabilities creates a high-stakes environment for investors navigating today's activist and judicial pressures.

Activist Investor Exit Triggers Immediate Selloff

Inclusive Capital Partners, led by Jeffrey Ubben, offloaded its full remaining position of 8.5 million Bayer shares overnight, raising approximately 318 million EUR at a priced level of 37.45 EUR per share. This represented a 2.6% discount to the prior Xetra closing price, highlighting limited institutional appetite for the stock at current levels. The sale, first reported by Bloomberg and confirmed by market sources, contributed to Bayer AG stock sliding as much as 3.7% intraday on Xetra, making it one of the weakest performers on the DAX index.

The activist fund had entered Bayer in early 2023, advocating for management changes including the hiring of an external CEO. Its departure signals a lack of progress on key value-unlocking initiatives, such as separating the crop science division or resolving litigation overhangs. Bayer AG stock was last seen on Xetra at around 37.65 EUR in real-time estimates, reflecting a 1-day drop of about 2.48% and a weekly decline of 6.47%.

Persistent Roundup Litigation Shadows Bayer's Recovery

At the core of Bayer's challenges lies the massive US litigation portfolio stemming from its 2018 acquisition of Monsanto, bringing with it over 165,000 Roundup-related lawsuits alleging carcinogenic effects from glyphosate-based products. Bayer has already provisioned tens of billions of euros for settlements, contributing to a 2025 net loss of 3.6 billion EUR largely attributable to legal costs. The stock's longer-term performance reflects this strain, down 44.71% over three years despite a 36.22% gain in the past six months on Xetra.

A pivotal US Supreme Court hearing scheduled for April could fundamentally alter this landscape, potentially undermining the basis for 65,000 pending cases. A favorable ruling might dismantle the legal foundation for many claims, providing much-needed relief to Bayer's finances. However, parallel state-level 'shield laws' have seen mixed success, with protections enacted in Georgia but failing in over a dozen other states, adding to short-term volatility. Bayer AG stock closed at 38.46 EUR on Xetra the prior day, with recent trading showing intraday lows around 37.05 EUR.

Recent Regulatory Wins Offer Glimmer of Pharma Strength

Contrasting the negative headlines, Bayer secured notable regulatory approvals in Japan, bolstering its pharmaceuticals division. Eylea 8 mg eye injection gained approval for a third retinal indication, targeting macular edema, while the MRI contrast agent Ambelvist (gadoquatrane) also received the nod. These milestones highlight Bayer's progress in ophthalmology and diagnostics, key growth areas amid patent cliffs elsewhere in its portfolio.

Such developments underscore the bifurcated nature of Bayer's business: a resilient pharma segment with blockbuster drugs like Xarelto and Eylea generating stable revenues, juxtaposed against volatile crop science exposed to commodity cycles and litigation. Analyst upgrades from firms like Oddo BHF to Outperform and UBS to Buy in recent weeks point to underlying operational momentum, with consensus P/E ratios projected at 19.7x for 2026 dropping to 12.3x in 2027 on Xetra-traded shares.

Why US Investors Should Monitor Bayer AG Stock Closely

For US investors, Bayer represents a unique transatlantic play with significant American market exposure, particularly in agriculture where Monsanto's legacy looms large. The US accounts for a substantial portion of Bayer's crop science sales, making domestic litigation outcomes directly material to earnings power. A Supreme Court win could unlock billions in trapped value, potentially catalyzing a re-rating of the stock from current depressed levels around 37-38 EUR on Xetra.

Moreover, Bayer's ADRs trade over-the-counter in the US, offering easy access without direct Xetra exposure, though liquidity remains thinner. With enterprise value at approximately 70 billion EUR and a free float of 100%, the stock trades at an EV/Sales multiple of 1.54x for 2026, appealing for value-oriented portfolios betting on legal resolution. US institutional ownership, including the now-exiting Inclusive Capital, underscores cross-border interest in Bayer's turnaround story.

Valuation Metrics Suggest Oversold Territory

Bayer AG stock's market capitalization hovers around 37.8 billion EUR on Xetra, with an enterprise value of 70 billion EUR reflecting substantial net debt from litigation provisions and past deals. Forward yields are modest at 0.59% for 2026 rising to 2% in 2027, prioritizing deleveraging over dividends. Compared to pharma peers, Bayer's multiples appear compressed, potentially offering upside if litigation risks abate.

Recent trading volumes spiked to over 8 million shares on March 20 on Xetra, indicating heightened interest amid analyst upgrades from Goldman Sachs and Barclays maintaining Buy ratings. Six-month performance of +36% contrasts with year-to-date gains of just 1.62%, highlighting episodic volatility tied to news flow. Investors eyeing entry points may find current levels attractive, provided they stomach legal uncertainties.

Key Risks and Open Questions Ahead

Despite positive regulatory news, Bayer faces elevated risks from adverse Supreme Court outcomes, potential escalation in Roundup claims, and activist pressure for structural changes like spinning off crop science. State shield laws provide patchy protection, while global agrochemical demand remains sensitive to trade tensions and weather events. Bayer AG stock's 52-week range on Xetra reflects this, with recent lows testing support levels amid the activist exit.

Management's focus on pipeline advancement in oncology, cardiology, and radiology must deliver to offset legacy burdens. With P/E expansion hinging on litigation clarity, any delays could prolong underperformance. US investors must weigh these factors against sector tailwinds in precision medicine and sustainable agriculture.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.